About
PhoreMost is a Cambridge UK-based biotechnology company dedicated to turning scientific breakthroughs into life-changing cancer therapies. The company's lead program, PMC-001, is a differentiated orally bioavailable, CNS-penetrant microtubule disruptor positioned to treat primary and metastatic brain cancers. The company is advancing PMC-001 to Phase 1/2a clinical evaluation in addition to progressing pipeline assets in Discovery.
Pipeline
PhoreMost is developing its pipeline of small molecule drugs, targeting cancers of high unmet clinical need
| Programme | Modality | Indication | Feasability | Discovery | Pre-Clinical | Phase 1 |
|---|---|---|---|---|---|---|
| PMC-001 | Small molecule | Primary and Secondary Brain Cancers | ||||
| PMC-002 | Small molecule | HPV+ Cancers | ||||
| PMC-003 | Bifunctional degrader | Oncology | ||||
Scroll / Drag to view
Partnering Opportunities
In addition to the programmes above, PhoreMost is also using its proprietary chemistry against multiple novel E3 ligases to develop next-generation targeted protein degradation therapeutics.
News
PhoreMost announces lead oncology programme and appoints Chief Medical Officer to support clinical entry
10th June 2026
PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics
7th May 2025
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes
10th September 2024
PhoreMost Achieves Second Milestone in Target Discovery Alliance with Boehringer Ingelheim
3rd June 2024
Contact us
We are interested in hearing from potential collaborators and employees from all pursuits to join with us in developing new therapies to unmet diseases.
+44 (0)1223 856 740
Moneta Building, B280, Babraham Research Campus, Cambridge, CB22 3AT